Citations

Clear

183 citation(s) found for "Sher-Lu, P".

Balancing Feasibility and Validity: A Delphi Consensus on Frailty Assessment Tools in Perioperative Care
Logvinov, Ilana , Pai, Sher-Lu

Mayo Clinic

Anesthesia & Analgesia | November 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1213/ane.0000000000008349 | PMID 43063977 Get It

In Response
Pai, Sher‐Lu , Harbell, Monica W. , Pai, Sher-Lu , Harbell, Monica W

Mayo Clinic

Anesthesia & Analgesia | July 1, 2026 | Volume: 143 | Issue: 2 | Pages: e28-e29

10.1213/ane.0000000000008152 | PMID 42385731 Get It

Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy
Kharfan-Dabaja, Mohamed A., Uyanik, Mehmet S., Sher, Taimur , Qin, Hong, Aljurf, Mahmoud, Kumar, A, Kharfan‐Dabaja, Mohamed A. , Tsalatsanis, Athanasios , Uyanik, Mehmet, Qin, Hong, Aljurf, Mahmoud , Chavez, Julio C

Mayo Clinic

Hematology/Oncology and Stem Cell Therapy | June 23, 2026 | Volume: 19 | Issue: 1 | Pages: 37-43

10.4103/hemoncstem.hemoncstem-d-26-00018 | PMID 42333073 Get It

Background: A diagnosis of cancer creates a stressful situation owing to the uncertainties related to the thought of possible suffering from complications associated with treatment toxicities, the fear of not responding to the prescribed treatment, or death. The prevalence of mental health disorders is relatively higher in cancer patients vis-à-vis the general population. Methods: We performed a retrospective cohort study to evaluate the impact of mental health disorders on outcomes of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR T-cell) therapy using data from the TriNetX research network. Results: A total of 1587 patients met the inclusion criteria (858 with a mental health diagnosis and 729 without). After propensity score matching for age and gender, 1320 patients were included in the analysis (660 in each group). The 1-year OS was higher in patients without a mental health disorder (76.0% versus 69.4%, P = 0.004). Patients with mental health disorders had a higher incidence of cytokine release syndrome (all grades) compared with those without (35.5% versus 27.6%, P < 0.001) and immune effector cell-associated neurotoxicity syndrome (all grades) (16.8% versus 10.1%, P < 0.001). Conclusions: These findings emphasize the importance of thorough psychiatric evaluation and management in patients receiving CAR T-cell therapy. Patients with mental health disorders may need significant assistance with coordinating medical services to better adhere to required care management. Future studies are needed to help determine whether preventive and real-time mental health interventions can favorably impact outcomes of these patients.
Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma
Berman, Zachary T. , Garza‐Ramos, Cynthia De la , Montazeri, Seyed Ali , Malone, Christopher D. , Sandow, Tyler, Gimenez, Juan , Young, Shamar, Fidelman, MD Nicholas, Pianka, Kurt, Sher, Alex, Vakil, Parmede , Wang, Melinda , Abounorinejad, Faraz, Johnson, Guy E. , Padia, Siddarth, Kim, Edward , Toskich, Beau B. , De la Garza-Ramos, Cynthia , Montazeri, S Ali , Fidelman, Nicholas , Pianka, Kurt T , Alamuri, Tharun , Chan, Shin Mei , Wang, Melinda , Abounorinejad, Faraz , Padia, Siddarth A , Kim, Edward , Toskich, Beau , Berman, Zachary T. , Malone, Christopher D , Sandow, Tyler Allan , Sher, Alex , Chan, Shin Mei , Som, Avik

Mayo Clinic

Radiology | May 5, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.251923 | PMID 42084516 Get It

Among patients with treatment-naive hepatocellular carcinoma, glass microsphere radiation segmentectomy before liver transplant achieved high rates of complete pathologic necrosis, which was positively associated with the number of optimized treatment parameter thresholds.
Lymphoma and long term outcomes after percutaneous coronary intervention
Reeves, I C R, Laenger, J L, Lewis, B L, Lugo-Fagundo, N L F, Umadat, G U, Sher, T S, Madison, T M, Elalfy, A E, Seby, R M S, Sabbagh, A E S El, Pillai, D P P, Gharacholou, S, Lugo‐Fagundo, Nahyr , Umadat, Goyal , Elalfy, Aya, Seby, Robert , Sabbagh, A. El, Pillai, Dilip, Gharacholou, S. Michael

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.1662 Get It

Abstract Background Cancer therapies have prolonged survival in lymphoma. However, lymphoma patients may develop significant coronary artery disease (CAD), which may be treated by percutaneous coronary intervention (PCI). The characteristics and outcomes of lymphoma patients treated by PCI are not well studied. Methods We reviewed lymphoma patients undergoing PCI at our institution between 2010 and 2020 and compared them to a cohort without cancer. Patient characteristics and predictors of long-term mortality and major adverse cardiac events (MACE) (death, myocardial infarction, target lesion revascularization) were studied using descriptive statistics and survival analysis utilizing a Cox proportional hazards model. Results Of the 11,953 patients in the study cohort, 83 had a history of lymphoma meeting study criteria. Lymphoma patients, as compared to non-lymphoma patients were similar with respect to age, sex, hypertension, diabetes, hyperlipidemia, prior MI, and prior PCI (all p=ns). Over a median follow-up of 3.9 (1.0, 5.0) years, the mortality at 5 years was higher in lymphoma versus non-lymphoma patients (47.5% vs 29.8%) (P=0.005) (Figure). After adjusting for age, sex, hypertension, diabetes, shock, smoking status, heart failure, and chronic renal disease, lymphoma was an independent predictor of mortality (OR 1.59; 95% CI 1.07-2.36, p=0.02). Lymphoma was not independently associated with MACE. Discussion Lymphoma patients undergoing PCI have significantly lower survival rates than non-cancer controls. After accounting for important cardiac risk factors, lymphoma was independently associated with higher long term mortality.
Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study
Habermann, T. M., Gertz, Morie A, Porrata, Luis, Johnston, Patrick B. , Lin, Y., Buadi, Francis K. , Dingli, David , Wang, Yucai, Leung, Nelson, Kourelis, Taxiarchis , Witzig, TE, Warsame, Rahma , Cook, Joselle, Sher, Taimur , Gertz, Morie A. , Leung, Nelson , Wang, Yucai , Gertz, Morie A , Buadi, Francis K , Wang, Yucai , Leung, Nelson , Kourelis, Taxiarchis , Witzig, T.E. , Warsame, Rahma , Cook, Joselle M , Rosenthal, Allison C, Tun, Han W , Dispenzieri, Angela , Dingli, David , Nishimura, Yoshito , Cook, Joselle , Rosenthal, Allison , Tun, Han W. , Dispenzieri, Angela

Mayo Clinic

Blood Advances | December 24, 2025 | Volume: 10 | Issue: 5 | Pages: 1487-1496

10.1182/bloodadvances.2025018324 | PMID 41441992 Get It

Abstract Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders anatomically classified by distribution (unicentric CD [UCD], oligocentric CD [oligoCD], or multicentric CD [MCD]). Human herpes virus 8–negative MCD is called idiopathic MCD (iMCD), which includes clinical subtypes with varying phenotypes and responses: TAFRO (thrombocytopenia, anasarca, fever, renal dysfunction and/or reticulin fibrosis, and organomegaly), IPL (idiopathic plasmacytic lymphadenopathy), and not otherwise specified. OligoCD has recently emerged as an intermediate form between UCD and MCD, with unclear clinical behavior, and IPL has not been validated in a Western cohort. We retrospectively analyzed 217 patients with CD evaluated at our institution between January 2004 and August 2024. Survival probabilities were compared using log-rank tests. Overall, 57% had UCD, 20% had oligoCD, and 23% had iMCD. Patients with oligoCD and iMCD more frequently exhibited systemic symptoms than those with UCD. Patients with oligoCD and iMCD had significantly shorter event-free survival (EFS) of 8.9 and 2.3 years, respectively, than those with UCD (not reached; P&lt; .001 and P&lt; .02). Among iMCD subtypes, iMCD-IPL demonstrated a longer EFS than iMCD-TAFRO (P = .02), with no deaths during the follow-up periods. The results validate oligoCD and iMCD-IPL as new subtypes in this Western cohort. The survival outcome in oligoCD was intermediate between UCD and iMCD, with only a subset of patients with oligoCD requiring systemic therapy. iMCD-IPL had a favorable survival outcome in this US cohort, similar to what has been reported in non-Western countries. Tailoring treatment strategies to disease subtypes and vigilant monitoring of oligoCD for progression may improve survival outcomes in CD.
Association of Vitamin D Deficiency with Diabetic Nephropathy in Type 2 Diabetes: A Hospital-Based Cross-Sectional Study
Bashir, Shafia, Ishaq, Geer Mohammad , Mushtaq, Insha, Ganie, Mohammad Ashraf, Wani, Imtiyaz, Alanazi, Muteb , Asiri, Ibrahim, Hussain, Arshad , Khan, Kashif Ullah , Anwar, Sirajudheen , Bashir, Shafia, Ishaq, Geer Mohammad , Mushtaq, Insha, Ganie, Mohammad Ashraf, Wani, Imtiyaz, Alanazi, Muteb , Asiri, Ibrahim, Hussain, Arshad , Khan, Kashif Ullah , Anwar, Sirajudheen

Mayo Clinic

Diseases | December 17, 2025 | Volume: 13 | Issue: 12 | Pages: 405

10.3390/diseases13120405 | PMID 41439946 Get It

Background/Objective: Diabetic nephropathy (DN), a key microvascular complication of type 2 diabetes (T2DM), drives significant morbidity, mortality, and healthcare costs. Vitamin D deficiency has been linked to renal dysfunction, but its role in DN remains unclear. This study assessed the association between vitamin D status and DN versus T2DM without nephropathy. Methods: This cross-sectional hospital-based study included 399 participants (299 DN, 100 T2DM without nephropathy) at a tertiary endocrine clinic. Demographic, clinical, and biochemical data, including serum 25(OH)D, were collected. Chi-square and Mann–Whitney compared categorical and continuous variables, respectively, and multinomial logistic regression assessed the association between vitamin D status and DN (p < 0.05). Results: Patients with DN were older (58.2 ± 7.95 vs. 51.4 ± 9.94 years, p < 0.001), had more advanced CKD (stages 2–3b: 84.6% vs. 20.0%, p < 0.001), and higher albuminuria (moderate: 80.3% vs. 19.0%; severe: 18.4% vs. 0%, p < 0.001). They also showed poorer glycemic control, elevated urea and creatinine, lower serum albumin, dyslipidemia, elevated liver enzymes, and higher uric acid (all p < 0.05). Vitamin D deficiency was more prevalent in DN (37.7% vs. 8.0%, p < 0.001). Unadjusted multinomial regression indicated that T2DM patients without nephropathy had a 91% lower risk of vitamin D deficiency (RRR 0.09; 95% CI 0.04–0.19, p < 0.001) and an 87% lower risk of insufficiency (RRR 0.13; 95% CI 0.05–0.26, p < 0.001) compared with DN patients. After adjusting for age, HbA1c, creatinine, duration of diabetes and eGFR, the reduced risk of deficiency remained significant (RRR 0.04; 95% CI 0.01–0.16, p < 0.001), while the association with insufficiency was no longer significant (p = 0.310). Conclusions: This study shows a significant association between vitamin D deficiency and diabetic nephropathy, though its cross-sectional design precludes causal inference. Reverse causality and residual confounding cannot be excluded. Patients with DN had poorer glycemic control, dyslipidemia, and renal function, along with more frequent vitamin D deficiency. Routine vitamin D monitoring may support early detection and risk stratification in T2DM.
Intracardiac thrombosis during liver transplantation: A 22-year single-institution cohort study
Pai, Sher‐Lu , Lee, Jennifer Y. , Sher, Taimur , Li, Zhuo , Perry, Dana K. , Logvinov, Ilana I. , Chadha, Ryan , Aniskevich, Stephen , Mao, Shennen A. , Lee, Jennifer , Chadha, Ryan , Pai, Sher-Lu , Aniskevich, Stephen , Mao, Shennen A , Logvinov, Ilana

Mayo Clinic

Liver Transplantation | December 12, 2025 | Volume: 32 | Issue: 4 | Pages: 633-637

10.1097/lvt.0000000000000774 | PMID 41384290 Get It

National cross-sectional Study to explore current state of patient awareness of multiple myeloma (MM) disease basics and its management: Identifying gaps and associations
Russell, Kenyot'a, Das, Saurav , Ailawadhi, Dhaani, Mondy, Jayla , Sher, Taimur , Fernandez, Andre, Flott, Caitlin, Chanan‐Khan, Asher , Russell, Kenyot'a, Parrondo, Ricardo D , Roy, Vivek , Ailawadhi, Sikander

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4587-4587

10.1182/blood-2025-4587 Get It

Abstract Background: MM is the second most common hematologic malignancy, which despite significant therapeutic advancements, remains incurable. The complexity of MM and its intricate management creates substantial informational demands for patients navigating their care. Methods: A cross-sectional survey study (Mayo Clinic IRB # 25-004671) was conducted to assess MM patients’ awareness about disease basics. A voluntary English language survey (47 questions) encompassing multiple domains of patient MM awareness was administered (REDCap) via the patient EMR portal (Mayo Clinic) and MM support groups nationally. Responses were analyzed using descriptive and inferential statistics (R; Bluesky Statistics, V 10.3.4). Multiple model logistic regression was used for multivariate analysis using age (≤70 or &gt;70 yrs), gender, education (high school or less vs bachelor's and above), income (≤$74999 vs ≥$75000) and insurance status (private vs public). Results: The survey was completed by 2353 patients (pts) with 2177 MM (83.4% active, 16.6% smoldering) and 176 MGUS. Among MM pts median age was 63 yrs with 52.5% males, 91.5% white and 95.7% non-Hispanic. 17.5% had a prior diagnosis of MGUS and 20.2% of smoldering MM prior to MM, and 79.5% were not aware of MM prior to their own diagnosis. Majority (77%) depended most on their doctors to gain MM information but 24.3% reported not having sufficient discussion about MM at diagnosis. 31.2% were not sure what type of MM they had, 22.9% could not correctly report the cell of MM origin (plasma cell), 40.6% did not receive MM stage information at diagnosis, 45.4% were either unsure or reported wrong risk factors for MM and 22% were unsure or mistaken about MM symptoms. Majority (62.9%) did not understand genetic risk categories of MM, 32.3% did not report adequate understanding of MM tests and 31.9% did not understand the difference between response and remission. 57.5% reported not understanding about MRD status and 57.1% never had MRD testing. Majority (86.8%) felt they got adequate opportunity to participate in treatment decisions but only 54.2% felt confident in managing MM with their current knowledge and 28.2% had not discussed their prognosis although 77.7% wanted to know about it. Majority (64.4%) felt they had knowledge gaps about MM and its management. Multivariate analysis showed that females were less likely (OR 0.67) while those with public insurance were more likely (OR 1.35) to report receiving adequate information at diagnosis. Older pts (OR 0.55), males (OR 0.43), with lower education (OR 0.5), lower income (OR 0.5) and public insurance (OR 0.72) were less likely to identify the cell of MM origin correctly. These same groups were significantly less likely to be aware of types of MM as well. Older pts (OR 0.73), with lower education (OR 0.6), lower income (OR 0.77) and public insurance (OR 0.76) were less likely to be aware of MM genetic risk categories. Females (OR 0.81), with lower education (OR 0.68) and lower income (OR 0.63) were less likely to understand MM lab tests. Females and those with lower income were significantly less likely to report receiving adequate information about treatment options. Females reported that they did not get adequate opportunities to participate in treatment decisions (OR 0.65). Older pts, and those with lower income, lower education or public insurance were less likely to understand minimal residual disease (MRD) and all these groups were less likely to have had MRD testing. Those with lower income (OR 0.75) and lesser education (OR 0.72) felt less confident in managing MM with current knowledge. Older pts, females and those with lesser education, lower income and public insurance were also significantly less likely to have discussed about MM prognosis. Conclusion: This study demonstrates substantial basic knowledge deficits integral to managing and prognosticating MM among patients. Patients from unfavorable sociodemographic-economic groups were more likely to have awareness gaps and report lack of information which is integral to having adequate understanding of MM being provided to them. These findings highlight the critical need for structured, comprehensive educational interventions that address fundamental disease concepts to empower pts, overcome healthcare disparities, and engage pts in shared decision-making.
Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)
Menezes, Ricardo de, Sledge, Hanna, Yadav, Kanika, Nayyar, Moez, Kapoor, Prashant , Sher, Taimur , Abdallah, Nadine , Lin, Yi, Flott, Caitlin, Yadav, Udit , Warsame, Rahma , Wiedmeier, Julia E. , Kourelis, Taxiarchis , Fernandez, Andre, Kumar, Shaji, Chanan‐Khan, Asher , Wiedmeier-Nutor, Julia E , Parrondo, Ricardo D , Menezes, Ricardo de, Nayyar, Madhavi, Bergsagel, P. Leif , Fonseca, Rafaël , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Roy, Vivek , Binder, Moritz , Chhabra, Saurabh , Rajkumar, S. Vincent , Gonsalves, Wilson I. , Cook, Joselle , Dingli, David , Muchtar, Eli , Leung, Nelson , Siddiqui, Mustaqeem , Kumar, Shaji , Ailawadhi, Sikander

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4585-4585

10.1182/blood-2025-4585 Get It

Abstract Background: The phase II and III GRIFFIN and PERSEUS studies evaluated DVRd vs. VRd in NDMM pts that were transplant eligible (TE). These studies included consolidation (cons) and dual agent maintenance (maint) with dara and len (DR). Little is known about the efficacy of DVRd in RW practice including frequency of bor use, use of cons, use of DR maint, and subsequent treatment after progression (PD) on DVRd. We aim to evaluate the RW efficacy of NDMM pts treated with DVRd across the tri-site Mayo Clinic Comprehensive Cancer (MCCC). Methods: We retrospectively analyzed the medical records of pts treated with DVRd between June 2018 and June 2024 at the MCCC. Outcomes were estimated using the Kaplan-Meier method. Results: 464 pts were included; 278 pts were male, and the median (m) age of MM diagnosis was 64 years (yr). 114 pts had ISS III, 205 pts had R-ISS III, 266 pts had high risk (HR) FISH, 80 pts had extramedullary disease, 165 pts had ultra HR disease (dz) (as per 2025 IMS/IMWG consensus), and 47 pts had renal insufficiency (RI) with creatinine &gt;2 mg/dL. Starting len dose was 25mg in 356 pts, 15 mg in 40 pts and ≤10mg in 65 pts. 399 pts received bor 1x per week and 63 2x per week, 91 pts received 1-2 cycles of a different regimen prior to DVRd due to hospitalization (n=23), RI (n=38), poor performance status (n=6), other (n=34). 315 (67.9%) pts underwent autologous transplant (ASCT). The m number of induction cycles was 5; 4 for pts who underwent ASCT and 6 for pts who did not. The best ORR to induction for pts who underwent ASCT was 98% with 247 (79%) achieving ≥VGPR, and 82 (26%) achieving minimal residual disease negativity (MRD-) to at least 10-5. The best ORR for pts who did not undergo ASCT was 87%. For those who underwent ASCT, (96% with melphalan 200mg/m2), the ORR at day 100 was 97% with 56% achieving MRD-. At 1-yr post ASCT, 30% (93/312) were MRD-. 42 pts (13%) received post ASCT cons with DVRd for a m of 2 cycles. 281 pts received post ASCT maint including 107 (38%) len, 53 (19%) bor-len, 91 (32%) dara-len, 14 (5%) dara, 16 (6%) other. 61(13%) pts had change in treatment, due to change to second line therapy (35; 55%), discontinuation (d/c) of len (11; 17%), d/c of dara (3; 5%), d/c of bor (15; 23%), d/c of dex (0; 0%). The m follow-up time for all pts was 26 months (mo) (17-39). The m PFS of pts who underwent ASCT was not reached (NR), and was 57 mo (52-NA) for pts who did not undergo ASCT. For pts who underwent ASCT, the PFS at 24mo for pts who did not have HR FISH was 93% (88-99%) compared to 80% (73-88%) for pts with HR FISH (p=0.12) and 77% (68-87%) for pts with ultra-HR dz (p=0.013).The PFS at 24mo of pts with RI who underwent ASCT was 81% (66-98%) compared to 86% (82-92%) for those without RI, p=0.57. The PFS at 24mo of pts with RI who did not undergo ASCT was 53% (28-100%) compared to 64% (55-75%) for those without RI, p=0.42. The ORR and MRD- rate for pts who received once-weekly bor was 94% and 24%, compared to 94% and 27% for pts who received 2x weekly bor (p=0.85, p=0.93). For pts who underwent ASCT, the PFS at 24mo for pts who received len maint was 91% vs. 83% for pts who receive dual agent maint (DR or VR) (p=0.25), although pts who got dual agent maint were more likely to have HR FISH than pts who received len maint (p&lt;0.001). The PFS at 24mo for pts that received post-ASCT cons was 91% compared to 85% for those that did not (p=0.53); pts who got post-ASCT cons were more likely to have HR FISH (p=0.07). For pts that underwent ASCT, the 3 yr PFS rate is 85% and the 3 yrs OS rate is 96%. For pts that did not undergo ASCT the 3 yrs PFS rate is 60% and the 3 yr OS rate is 85%. 55 pts had functional HR (FHR) MM (relapse within 18 mo) and m PFS for FHR pts who underwent ASCT was 15 mo (11-NA), while m PFS was NR for pts without FHR MM (p&lt;0.001). 79 pts relapsed after 1st line DVRd. The most common 2nd line therapies (tx) were dara-carfilzomib (K)-D, dara-pomalidomide(P)-D, KPD, and other. The m follow-up time from 2nd line tx was 10 mo, the best ORR to 2nd line tx was 76%, and the m PFS with 2nd line tx was 18 mo (7-NA). Conclusion: In this RW analysis, the efficacy and survival outcomes of NDMM pts treated with DVRd was comparable to that reported in the PERSEUS and GRIFFIN trials, although MRD- rates appear lower. DR maint and post-ASCT cons use was not common and was used more frequently in pts with HR FISH. Pts can be effectively salvaged following PD on front-line DVRd with available tx.